Proteus pins hopes on gene discovery

Paul Rodgers explains why large drug firms suddenly want to talk to a small biotech company

LONG-SUFFERING investors in Proteus, a biotechnology company, may be sceptical, especially when they see its financial results on Thursday. But Jurek Sikorski, the new chief executive, is confident the company is about to turn the corner, thanks to a new technology he believes is capable of targeting the genes behind diseases ranging from rheumatoid arthritis to cancer and Aids.

Proteus, like most biotech companies, has had a turbulent life. Floated in 1990 at 84p, its shares soared to about 500p two years ago, then collapsed after UBS quit as joint broker when it failed to meet projections in the original prospectus. The stock is now languishing back at 88p, and the markets are braced for another annual loss, probably around pounds 7m, to be announced on Thursday.

But the company, based in Macclesfield, Cheshire, is now in serious talks through Progene, a joint venture with America's Genelabs Technologies, with eight international drug companies about applying its computer design techniques to formulate molecules that can block individual strings of DNA. If even a few of them sign development agreements, Proteus will have a healthy stream of revenues for the first time.

Promises of deals to come are a dime a dozen in the biotech sector, but Proteus's claim is more than just hot air. The head of cancer research at one US drugs giant called the advance the best thing he had seen in 10 years. "They came to us two years ago and, in an appropriately arrogant fashion, we kicked them out, saying that what they proposed couldn't be done. They came back 18 months later with the evidence that they'd succeeded."

Deals between other small biotechnology firms and large pharmaceutical companies typically involve a one-off cheque at the start of a development programme, and additional payments as set milestones are passed. For shareholders, the big payback will only come after a drug gets regulatory approval for use on human patients and fat royalties start to flow.

Proteus had originally aimed to sell the computer software that biochemist Dr Barry Robson began developing at the University of Manchester to pharmaceutical companies. But when they balked at the price tag, it decided to apply the system itself. Some 30 projects were spawned, fragmenting the research effort. When Mr Sikorski was brought in nine months ago, he pared the number of projects down to a dozen. Among them was Progene.

Many diseases have links to DNA, the spiralling ladder-like molecule in the nucleus of each cell that governs its biochemistry. Different sections of the molecule - the genes - are coded to represent proteins, the building blocks of life. Most of the genes are necessary for the cell's well-being but a few, such as cancer-causing oncogenes, are not. The code is written with four base-pairs, each one representing a slightly different-shaped rung on the DNA ladder.

Each gene is switched on and off by molecules called transcription factors, which bind to the DNA in front of the protein-coding sections, like grotesquely shaped men with their arms and legs wrapped through and around the rungs of a ladder. Some naturally occurring drugs also bind to these sites, blocking the transcription factors and thus the copying process.

These molecules are small, however, usually covering just four of the DNA molecule's rungs, so they have a wide choice of possible binding sites. A drug that was 12 to 16 base-pairs long is so complicated it would fit snugly only when it found the target segment. It would therefore be more effective, require a lower dose, and be less likely to cause side-effects.

Progene set about building such molecules by testing known DNA binding drugs with a patented Genelabs process called Merlin to see which combinations of base-pairs they stuck to most firmly. Each four-rung drug was tried against every possible combination of four base-pairs, 256 in all. The result was a catalogue of about 30 building blocks.

Proteus then used its custom computer software, Prometheus, to combine the building blocks into 12 base-pair molecules that match specific strings of DNA. The automated design process usually comes up with several candidates, which are then built and sent to Genelabs for further testing to ensure the new drugs do block transcription factors.

If the large drug companies sign on the dotted line, their role will be to supply Progene with DNA strings that they have linked to specific diseases. The drugs will still have to show that they can pass through the blood stream without breaking down, and that they can sneak through the cellular and nuclear membranes to reach the DNA. Finally they will have to go through tests to prove that they are safe.

Start your day with The Independent, sign up for daily news emails
Arts and Entertainment
Attenborough with the primates
tvWhy BBC producers didn't want to broadcast Sir David Attenborough's famed Rwandan encounter
News
people
News
Campbell: ‘Sometimes you have to be economical with the truth’
newsFormer spin doctor says MPs should study tactics of leading sports figures like José Mourinho
News
news
ebooks
ebooksA special investigation by Andy McSmith
Voices
Lance Corporal Joshua Leakey VC
voicesBeware of imitations, but the words of the soldier awarded the Victoria Cross were the real thing, says DJ Taylor
Life and Style
Alexander McQueen's AW 2009/10 collection during Paris Fashion Week
fashionMeet the collaborators who helped create the late designer’s notorious spectacles
Sport
football
News
i100
News
Perry says: 'Psychiatrists give help because they need help. You would not be working in mental health if you didn't have a curiosity about how the mind works.'
people
Latest stories from i100
Have you tried new the Independent Digital Edition apps?
Independent Dating
and  

By clicking 'Search' you
are agreeing to our
Terms of Use.

iJobs Job Widget
iJobs Money & Business

SThree: HR Benefits Manager

£40000 - £50000 per annum + pro rata: SThree: SThree Group have been well esta...

Recruitment Genius: Office Manager / Financial Services

£30000 - £37000 per annum: Recruitment Genius: Established in 1999, a highly r...

Jemma Gent: Year End Accountant

£250-£300 Day Rate: Jemma Gent: Are you a qualified accountant with strong exp...

Jemma Gent: Management Accountant

£230 - £260 Day Rate: Jemma Gent: Do you want to stamp your footprint in histo...

Day In a Page

War with Isis: Fears that the looming battle for Mosul will unleash 'a million refugees'

The battle for Mosul will unleash 'a million refugees'

Aid agencies prepare for vast exodus following planned Iraqi offensive against the Isis-held city, reports Patrick Cockburn
Yvette Cooper: We can't lose the election. There's too much on the line

Yvette Cooper: We can't lose the election. There's too much on the line

The shadow Home Secretary on fighting radical Islam, protecting children, and why anyone in Labour who's thinking beyond May must 'sort themselves out'
A bad week for the Greens: Leader Natalie Bennett's 'car crash' radio interview is followed by Brighton council's failure to set a budget due to infighting

It's not easy being Green

After a bad week in which its leader had a public meltdown and its only city council couldn't agree on a budget vote, what next for the alternative party? It's over to Caroline Lucas to find out
Gorillas nearly missed: BBC producers didn't want to broadcast Sir David Attenborough's famed Rwandan encounter

Gorillas nearly missed

BBC producers didn't want to broadcast Sir David Attenborough's famed Rwandan encounter
Downton Abbey effect sees impoverished Italian nobles inspired to open their doors to paying guests for up to €650 a night

The Downton Abbey effect

Impoverished Italian nobles are opening their doors to paying guests, inspired by the TV drama
China's wild panda numbers have increased by 17% since 2003, new census reveals

China's wild panda numbers on the up

New census reveals 17% since 2003
Barbara Woodward: Britain's first female ambassador to China intends to forge strong links with the growing economic superpower

Our woman in Beijing builds a new relationship

Britain's first female ambassador to China intends to forge strong links with growing economic power
Courage is rare. True humility is even rarer. But the only British soldier to be awarded the Victoria Cross in Afghanistan has both

Courage is rare. True humility is even rarer

Beware of imitations, but the words of the soldier awarded the Victoria Cross were the real thing, says DJ Taylor
Alexander McQueen: The catwalk was a stage for the designer's astonishing and troubling vision

Alexander McQueen's astonishing vision

Ahead of a major retrospective, Alexander Fury talks to the collaborators who helped create the late designer's notorious spectacle
New BBC series savours half a century of food in Britain, from Vesta curries to nouvelle cuisine

Dinner through the decades

A new BBC series challenged Brandon Robshaw and his family to eat their way from the 1950s to the 1990s
Philippa Perry interview: The psychotherapist on McDonald's, fancy specs and meeting Grayson Perry on an evening course

Philippa Perry interview

The psychotherapist on McDonald's, fancy specs and meeting Grayson Perry on an evening course
Bill Granger recipes: Our chef recreates the exoticism of the Indonesian stir-fry

Bill Granger's Indonesian stir-fry recipes

Our chef was inspired by the south-east Asian cuisine he encountered as a teenager
Chelsea vs Tottenham: Harry Kane was at Wembley to see Spurs beat the Blues and win the Capital One Cup - now he's their great hope

Harry Kane interview

The striker was at Wembley to see Spurs beat the Blues and win the Capital One Cup - now he's their great hope
The Last Word: For the good of the game: why on earth don’t we leave Fifa?

Michael Calvin's Last Word

For the good of the game: why on earth don’t we leave Fifa?
HIV pill: Scientists hail discovery of 'game-changer' that cuts the risk of infection among gay men by 86%

Scientists hail daily pill that protects against HIV infection

Breakthrough in battle against global scourge – but will the NHS pay for it?